Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05708352

A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment

Led by Cedars-Sinai Medical Center · Updated on 2026-05-06

170

Participants Needed

5

Research Sites

52 weeks

Total Duration

On this page

Sponsors

C

Cedars-Sinai Medical Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of a Ketogenic Diet versus a Standard Anti-Cancer Diet in patients newly diagnosed with glioblastoma multiforme. This Phase 2 randomized study involves 170 patients who all will receive standard of care treatment for their glioblastoma. The study aims to determine if the Keto Diet improves overall survival compared to the Standard Anti-Cancer Diet when combined with usual treatments. Participants are randomly assigned to one of two groups: an intensive 18-week Keto Diet managed by trained research dietitians, or a Standard Anti-Cancer Diet guided by dietitians using resources focused on low-fat foods like fruits, vegetables, and whole grains. Both groups receive dietitian support, and the Keto Diet group will track daily ketone and glucose levels to monitor adherence. During the study, participants undergo various assessments including overall survival monitored up to 18 months from the start, health-related quality of life evaluations, progression-free survival, cognitive performance tests, and physical activity measurements for up to 18 weeks. Researchers will also monitor adherence to the dietary interventions and safety throughout the study period.

CONDITIONS

Brief Title

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years or older
  • Newly diagnosed glioblastoma within 2 months of initial diagnosis by histopathology
  • Not started standard of care chemotherapy and/or radiation therapy for glioblastoma
  • Karnofsky Performance Status (KPS) 70 or higher
  • Ability to read, write, and understand English or Spanish
  • Written informed consent obtained and ability to comply with study requirements
Not Eligible

You will not qualify if you...

  • Patients with recurrent glioblastoma
  • Genetic disorders affecting lipid metabolism, including pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects
  • Inability to reduce steroid use below 8mg dexamethasone per day or equivalent
  • Body Mass Index (BMI) less than 21 kg/m2 unless deemed safe by the Principal Investigator
  • Currently pregnant or nursing
  • Receiving other experimental therapies (off-label therapy allowed)
  • Comorbidities limiting ability to complete the study
  • Food preferences incompatible with Keto Diet
  • Use of pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants (removable hearing aids allowed) unless deemed safe by the Principal Investigator
  • Inability to participate in standard of care MRIs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Outpatient Treatment

Duration - 18 weeks

Participants follow either an intensive 18-week ketogenic diet or standard anti-cancer diet guidance alongside standard-of-care treatment for glioblastoma.

Regular dietitian sessions during the 18-week intervention

Follow-up

Duration - Up to 18 months from baseline

Participants are monitored for overall survival and health outcomes up to 18 months from baseline after completion of dietary intervention.

Visits based on standard clinical follow-up schedules

Trial Site Locations

Total: 5 locations

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

2

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

3

Pacific Neuroscience Institute / Saint John's Cancer Institute

Santa Monica, California, United States, 90404

Actively Recruiting

4

Duke University

Durham, North Carolina, United States, 27705

Actively Recruiting

5

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Withdrawn

Loading map...

Research Team

C

Clinical Trial Recruitment Navigator

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 1 Safety and Dose Finding Study of 131I-TLX101 Plus ...

Neoplastic Disease

Actively Recruiting

6 locations

FRONTIER: A Feasibility Study to Evaluate the Safety of the ...

Glioblastoma Multiforme

Actively Recruiting

9 locations

A Prospective, Randomized Study to Evaluate Bevacizumab With...

Glioblastoma Multiforme

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here